• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Structure Therapeutics (GPCR) After Wider Q3 Losses Still Screens Cheap On Obesity Trial Promise

    Simply Wall St·11/12/2026 02:33:52
    Listen to the news

    Structure Therapeutics (GPCR) reported third quarter results that widened its loss to US$144.76 million as spending rose on two Phase 3 obesity pill trials, keeping attention on cash burn and upcoming clinical milestones.

    At a share price of US$20.95, Structure Therapeutics has seen a sharp reset, with the 90 day share price return down 61.57% and the year to date share price return down 69.25%, while the 1 year total shareholder return has fallen 40.14%. This suggests enthusiasm has cooled even as recent Phase 3 spending and clinical updates keep attention on future trial outcomes and cash usage.

    Spot emerging biopharma ideas alongside Structure Therapeutics by scanning our hand picked 19 high quality undiscovered gems for early stage companies with strong fundamentals and under the radar potential.

    Structure Therapeutics now trades at a steep discount after its selloff, yet is backed by Phase 3 obesity programs and US$1.4b in net cash. Does that combination still justify today’s price?

    Most Popular Narrative: 80% Undervalued

    On the analyst consensus Narrative on Simply Wall St, Structure Therapeutics screens as deeply undervalued, with a fair value of $105.78 against the last close at $20.95, anchoring the discussion in long term obesity drug expectations and execution risk.

    Scaling of oral GLP‑1 use in obesity treatment, with about 1.4 million U.S. patients and roughly 17% market share within months of launch and management expectations that oral agents could reach around half of the market by 2030, supports a long runway for aleniglipron to add incremental revenue and earnings power if it reaches the market.

    See why 1 investors see Structure Therapeutics as 80% undervalued.

    Result: Fair Value of $105.78 (UNDERVALUED)

    Still, the narrative around Structure Therapeutics can shift quickly if ACCG‑2671’s tolerability issues persist or if obesity drug competition pressures the lofty P/E assumptions embedded in analyst models.

    Find out about the key risks to this Structure Therapeutics narrative.

    Next Steps

    Sentiment around Structure Therapeutics is divided, with clear concerns and real optimism sitting side by side. Move quickly and weigh the trade offs yourself by checking the 1 key reward and 3 important warning signs.

    Looking for more investment ideas beyond Structure Therapeutics?

    Do not stop with a single ticker. Put Structure Therapeutics in context by lining it up against other opportunities that might suit your risk tolerance and income goals.